Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas

Acta Neuropathologica

Volumn 101, Issue 3, 2001, Pages 185-189

  Watanabe, Takao ^a   Nakamura, Mitsutoshi ^a   Yonekawa, Yasuhiro ^b   Kleihues, Paul ^a   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Homozygous deletion; Oligodendroglioma; P14ARF; P16INK4a; Promoter hypermethylation

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSYLATION FACTOR; CYCLIN DEPENDENT KINASE 4; GENE PRODUCT; PROTEIN MDM2; PROTEIN P16; PROTEIN P53; RIBOSOME PROTEIN;

ANAPLASTIC CARCINOMA; ARTICLE; CELL CYCLE; CHROMOSOME 9P; CONTROLLED STUDY; DNA METHYLATION; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GENETIC ANALYSIS; GENETIC CODE; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; TUMOR CLASSIFICATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DELETION; GENE SILENCING; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; OLIGODENDROGLIOMA; PROMOTER REGIONS (GENETICS); PROTEINS; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0035101576     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004010000343     Document Type: Article

References (37)

1. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors
2. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
3. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
4. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas
5. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
6. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation
7. INK4a methylation and p53 mutational status
8. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas
9. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with LOH on chromosome 10q25-qter
10. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
11. 1-S transition control gene abnormalities
12. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
13. p16 is a major inactivation target in hepatocellular carcinoma
14. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2
15. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis
16. Pathology and genetics of tumors of the nervous system
17. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma
18. Genetic aberrations in oligodendroglial tumors: An analysis using comparative genomic hybridization (CGH)
19. Molecular genetic evidence for subtypes of oligoastrocytomas
20. Regional DNA hypermethylation at D17S5 precedes 17p structural changes in the progression of renal tumors
21. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
22. Oligodendroglioma incidence and biological behavior in a defined population
23. Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers
24. p53 mutations in nonastrocytic human brain tumors
25. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
26. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
27. Epidermal growth factor receptor expression in oligodendroglial tumors
28. Evaluation of cell proliferation, epidermal growth factor receptor, and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendroglioma
29. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas
30. Pathology of Tumors of the nervous system
31. Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors
32. Brain tumors
33. Cancer cell cycles
34. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
35. INK4a genes in human esophageal squamous cell carcinoma
36. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
37. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas